用利伐沙班可能产生什么副作用？

It is an oral, bioavailable factor Xa inhibitor that selectively blocks the active site of factor Xa and does not require cofactors (such as antithrombin III) to exert activity. Factor X is activated into factor Xa (FXa) through endogenous and exogenous pathways, which plays an important role in the coagulation cascade. Rivaroxaban inhibits the activity of Factor Anti-factor Xa activity is also affected by rivaroxaban.

As we all know, taking any drug has side effects, so what are the possible side effects of taking Varoxaban?

1. Bleeding risk; in the ROCKET AF trial, the most common adverse reaction related to permanent discontinuation was bleeding events, with an incidence rate of 4.3% in the rivaroxaban group and 3.1% in the warfarin group. The incidence of discontinuation due to non-hemorrhagic adverse events was similar in both treatment groups. 2. Spinal/epidural hematoma. 3. The risk of stroke increases after early discontinuation of medication in patients with valvular atrial fibrillation; 4. Blood and lymphatic system diseases: agranulocytosis, thrombocytopenia; 5. Gastrointestinal diseases: retroperitoneal hemorrhage; 6. Hepatobiliary diseases: jaundice, cholestasis, hepatitis (Including liver cell damage); 7. Immune system diseases: hypersensitivity reaction, allergic reaction, anaphylactic shock, angioedema; 8. Nervous system diseases: cerebral hemorrhage, subdural hematoma, epidural hematoma, hemiparesis; 9. Skin and subcutaneous tissue: Stevens-Johnson syndrome.

In addition, some patients cannot use rivaroxaban:

1. Patients who are allergic to rivaroxaban or any excipients in the tablets. 2. Patients with clinically obvious active bleeding. 3. Lesions or conditions with a significant risk of major bleeding, such as current or recent gastrointestinal ulcers, malignant tumors with a high risk of bleeding, recent brain or spinal injury, recent brain, spine or eye surgery, recent intracranial hemorrhage, known or suspected esophageal varices, arteriovenous malformations, vascular aneurysms or major intravertebral intracranial vascular malformations. 4. Except in the case of switching to or from rivaroxaban from other treatments, or the administration of unfractionated heparin (UFH) doses required to maintain central venous or arterial catheters, concomitant treatment with any other anticoagulants is prohibited, such as UFH, low molecular weight heparins (enoxaparin, dalteparin, etc.), heparin derivatives (fondaparinux, etc.), oral anticoagulants (warfarin, apixaban, dabigatran, etc.). 5. Patients with liver disease associated with coagulation abnormalities and clinically relevant bleeding risks, including patients with cirrhosis reaching Child Pugh classes B and C. 6. Pregnant and lactating women.

The above is the content of side effects, I hope it can help you.